
Opinion|Videos|December 20, 2024
Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024
Author(s)Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses how emerging trends in targeted therapies, immunotherapies, and precision medicine presented at ASH 2024 are addressing unmet needs in the management of hematologic cancers and shaping future treatment strategies.
Advertisement
Video content above is prompted by the following:
- Coming into ASH 2024, what would you consider to be the largest unmet needs in the management of hematologic cancers?
- What are the latest trends and innovations you have observed in the treatment and management of hematologic cancers leading up to and coming out of ASH 2024?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Dual JAK Inhibition Demonstrates Efficacy in Progressive Nonsegmental Vitiligo
2
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
3
Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS
4
ERS Posters Showcase Nerandomilast Benefits in IPF, ILD
5